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Background: The membrane attack complex (MAC) is a key player in the pathogenesis of age-related macular
degeneration (AMD) and is a putative activator of the NLRP3 inflammasome. Amyloid beta (Aβ), a component of
drusen deposits, has also been implicated in inflammasome activation by our work and those of others. However,
the interactions of MAC and Aβ are still poorly understood, especially their roles in aging and retinal degenerative
pathologies. Since inflammasome activation may represent a key cellular pathway underlying age-related chronic
inflammation in the eye, the purpose of this study is to identify the effects associated with MAC and inflammasome
activation in the retinal pigment epithelium (RPE)/choroid and to evaluate the therapeutic merits of MAC suppression.
Methods: Adult Long-Evans rats were divided into treatment and control groups. Treatment groups received oral aurin
tricarboxylic acid complex (ATAC), a MAC inhibitor, in drinking-water, and control groups received drinking-water alone
(No ATAC). Groups were sacrificed at 7.5 or 11.5 months, after approximately 40 days of ATAC treatment. To study
age-related changes of Aβ and MAC in RPE/choroid, naive animals were sacrificed at 2.5, 7.5, and 11.5 months. Eye
tissues underwent immunohistochemistry and western blot analysis for MAC, Aβ, NF-κB activation, as well as cleaved
caspase-1 and IL-18. Vitreal samples were collected and assessed by multiplex assays for secreted levels of IL-18 and
IL-1β. Statistical analyses were performed, and significance level was set at p≤ 0.05.
Results: In vivo studies demonstrated an age-dependent increase in MAC, Aβ, and NF-κB activation in the RPE/choroid.
Systemic ATAC resulted in a prominent reduction in MAC formation and a concomitant reduction in inflammasome
activation measured by cleaved caspase-1 and secreted levels of IL-18 and IL-1β, but not in NF-κB activation. In vitro
studies demonstrated Aβ-induced MAC formation on RPE cells.
Conclusions: Age-dependent increases in Aβ and MAC are present in the rodent outer retina. Our results suggest that
suppressing MAC formation and subsequent inflammasome activation in the RPE/choroid may reduce chronic
low-grade inflammation associated with IL-18 and IL-1β in the outer retina.
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Age-related macular degeneration (AMD), the leading
cause of irreversible blindness in the elderly in developed
countries, is a condition of the central retina, character-
ized by retinal pigment epithelium (RPE) atrophy and
photoreceptor loss. Advanced chronological age is an
important risk factor for AMD. In North America, the
prevalence of AMD increases dramatically with age from
10 % in individuals at 55 to 65 years of age, to 30 % at
75 to 85 years of age [1]. Key to understanding the ef-
fects of aging on the pathogenesis of retinal degenerative
diseases are the cellular pathways that become dysregu-
lated with age [2–4].
For example, aging is associated with the dysregulation
in the complement cascade, part of the innate immune
response. The complement cascade causes opsonization
and agglutination, as well as cell lysis by the formation
of the membrane attack complex (MAC) [5]. Genetic
studies showed that certain variants of the complement
factor H (CFH) gene, an inhibitor of the alternative
pathway, can increase the risk of AMD by up to sixfold
in patients with the at-risk variant [6]. Postmortem eyes
genotyped for CFH at-risk variants have increased MAC
levels in the RPE/choroid [7, 8]. Moreover, in dry AMD
patients, those with a CFH Y402H variant have elevated
systemic levels of interleukin-6 (IL-6), tumor necrosis
factor (TNF-α), and IL-18 [9]. In addition to genetic influ-
ences, aging also contributes to the dysregulation of the
complement system, as evidenced by the association of ac-
tivated complement products and increased MAC depos-
ition in the RPE/choroid with advanced age [10–13].
While MAC deposition may cause cell lysis, it may also
occur at sublytic levels that promote chronic, low-grade
pro-inflammation. This type of chronic, local inflamma-
tion in the outer retina has been hypothesized to lead to
degenerative changes in RPE function [14]. Recent studies
have suggested that MAC may mediate activation of the
NLRP3 inflammasome [15, 16]. The inflammasome is a
multi-protein complex that activates caspase-1 and pro-
duces the pro-inflammatory cytokines IL-1β and IL-18,
which in turn have been linked to RPE atrophy [17, 18].
Whether MAC promotes inflammasome activation in the
RPE/choroid is not known and is the premise of this
study. We postulate that sublytic MAC increases with age,
promotes activation of the inflammasome, and thereby,
dysregulates RPE function. To ameliorate MAC-induced
inflammasome activation on RPE, we also explore the ef-
fects of an agent, aurin tricarboxylic acid complex
(ATAC), which has been shown to inhibit MAC formation
in mice and humans. Specifically, ATAC acts both to in-
hibit the formation of the C3 convertase and to block the
addition of C9 to the C5b-8 complex and thereby inhibits
MAC [19, 20]. Here, we examine the age-related increase
in MAC, the efficacy of ATAC in lowering levels ofsublytic MAC, and a subsequent, corresponding reduction
in inflammasome activation in the rat RPE/choroid.
Methods
In vivo studies
The animal procedures were approved by the Animal
Care Committee of the University of British Columbia,
conformed to the guidelines of the Canadian Council on
Animal Care and were in accordance with the Reso-
lution on the Use of Animals in Research of the Associ-
ation of Research in Vision and Ophthalmology. Adult
Long-Evans rats (Charles River, Wilmington MA) were
divided into four groups. Group 1 (N = 6) comprised 6-
month-old rats treated with oral administration of
ATAC for 40 days and sacrificed at the age of 7.5 months.
A dosage of 60 mg/100 mL (in drinking-water) was
chosen based on efficacy observed in an earlier study
[19]. Group 2 (N = 6) comprised untreated 6-month-old
rats (controls) sacrificed at the age of 7.5 months. Group
3 (N = 6) comprised 10-month-old rats treated with
ATAC in drinking-water (60 mg/100 mL) for 40 days and
sacrificed at the age of 11.5 months. Group 4 (N = 6) com-
prised untreated 10-month-old rats (controls) sacrificed at
11.5 months. Additional untreated naive animals were
sacrificed at 2.5, 6, 7.5, or 11.5 months, and retinal tissues
were used to demonstrate age-related changes in MAC,
Aβ, and NF-κB activation. At the study endpoints, animals
were anesthetized, whole blood drawn for serum analysis,
and then euthanized. Eyes were immediately enucleated
and frozen (western blot and ELISA) or fixed in 4 % para-
formaldehyde in Dulbecco’s phosphate-buffered saline
(Invitrogen, Carlsbad CA) for 48–72 h prior to embedding
in paraffin.
Fibrillar Aβ1–40 preparation
The lyophilized, synthetic Aβ1–40 peptide in its HCl salt
form was purchased from American Peptide (Sunnyvale,
CA). We chose Aβ1–40 peptide over its structurally simi-
lar but more toxic, Alzheimer’s disease-specific, form of
Aβ1–42 peptide based on earlier studies that demon-
strated the presence of Aβ1–40 in drusen deposits in
postmortem human eyes and its effects on upregulation
of complement genes in RPE cells in vitro [21, 22].
Fibrillar Aβ1–40 was prepared according to published
protocols [23, 24]. Briefly, the synthetic Aβ1–40 peptide
was reconstituted in sterile distilled H2O and incubated
at room temperature for 30 min, then evaporated by
speed vacuum for 1.5 h resulting in thin transparent
Aβ1–40 peptide film. Aβ1–40 peptide film was reconsti-
tuted in 100 % dimethyl sulfoxide to a concentration of
1 mM, and further diluted in Tris-buffered saline (TBS;
20 mM Tris-HCl, 100 mM NaCl, pH 7.4, 37 °C) to pro-
duce the Aβ1–40 stock solution of 100 μM. A longitudinal
incubation assay consisting of six sampling time points at
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tions for fibrillar Aβ1–40. Based on the protein separation,
the sample at 1-week incubation time was selected, due to
its higher fibrillar and lower oligomeric contents, which
was then further diluted to 0.3 μM (final concentration)
for the in vitro stimulation studies (Fig. 2) [22, 25–27].In vitro complement activation assay on ARPE-19 cells
An in vitro assay was used to assess whether the fibrillar
Aβ1–40 induces MAC formation and deposition on ARPE-
19 cells. Briefly, cells were seeded and cultured in 8-
chambered glass slides. Normal human serum (NHS)
(25 %) (CompTech, Tyler, TX) was added to the cell cul-
tures with 0.3 μM fibrillar Aβ1–40 for 24 h. Positive controls
included zymosan stimulation (10 μg/ml, Sigma Aldrich,
St. Louis MO) with 25 % NHS. Negative controls included
25 % heat-inactivated NHS (HI-NHS) with fibrillar Aβ1–40
or zymosan, and serum-free medium with 25 % NHS or
HI-NHS. MAC formation was detected by immunocyto-
chemistry (Table 1) and quantified as the percentage of
RPE cells positive for MAC compared to the total number
of cells per × 40 field. The experiments were done in hexa-
plicates for each stimulation condition (N = 6).Quantification of ATAC and CH50 assay
ATAC synthesis and its serum concentration analysis
followed published methods [19, 20]. The final ATAC
concentration was expressed in μg per 500 μL of blood
(N = 6). A CH50 hemolysis assay was used to assess com-
plement activation in rat serum before and after ATAC
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Paraffin-embedded eye tissues were prepared and sec-
tioned following established protocols [28]. Sections
from the paired groups (7.5 m ATAC and No ATAC;
11.5 m ATAC and No ATAC) and the three age groups
(2.5, 7.5, and 11.5 m) were processed simultaneously in
order to make intensity comparisons. Primary antibodies
targeting MAC, IL-18, and Aβ are described in Table 1.
For the negative control sections, the primary antibody
was replaced with a matched non-specific isotype IgG
(Sigma Aldrich). For visualization, the slides were de-
veloped using either the Vector® VIP substrate kit or
Vector® AEC substrate kit.
MAC, Aβ, and IL-18 immunoreactivity was scored in a
masked fashion and semi-quantitatively based on a 0–3
point scale (see Fig. 1 legend). Analysis and micrographs
were taken using a × 60 objective lens and × 10 eyepieces
(N = 3). The immunoreactivity scores of MAC, Aβ, and
IL-18 were averaged and normalized to the 7.5-month-old
group or the untreated control group (No ATAC).
To detect the active NF-κB, an antibody against the
NF-κB p65 subunit was used (Table 1). Immunoreac-
tivity was scored quantitatively, in a masked fashion,
using a × 60 objective lens and × 10 eyepieces (N = 3).
Positive RPE nuclei were identified as containing both
the red (AEC) chromogen and blue hematoxylin coun-
terstain, thus resulting in a purple appearance distinct
from the unlabeled RPE nuclei that were blue in color
from only the hematoxylin counterstain. The number
of NF-κB positive nuclei was converted to percentage
of all RPE nuclei in the sample area, and normalized to




























BioLegend, Dedham, MA Western blot
EMD Millipore, Billerica, MA Western blot
Fig. 1 (See legend on next page.)
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Fig. 1 Age-dependent increases of ocular MAC, Aβ and NF-κB. a Western blot analysis revealed increasing MAC levels in the rat RPE/choroid with
age from 2.5 to 11.5 months old (Kruskal-Wallis, p≤ 0.05). b Western blot analysis showed enhanced accumulation of high-molecular weight Aβ
(MW > 95 kDa) in the rat RPE/choroid with age from 2.5 to 11.5 months old (Kruskal-Wallis, p≤ 0.05). c ELISA measurements showed a dramatic
increase in the soluble Aβ levels in the vitreous fluids of the 11.5 months old (599.1 pg/mL) compared to the 6 months old group (7.5 pg/mL)
(Mann-Whitney, p≤ 0.05). d, e Analysis of MAC deposition (d) or Aβ (e) in rat RPE/choroid demonstrated a significant increase in immunoreactivity
with increasing age, with data normalized to the younger age group of 7.5 months (Mann-Whitney, p≤ 0.05). f NF-κB activation in RPE increased
with age. The percentage of RPE cells with nuclear labeling of translocated NF-κB p65 subunit was higher in the retina of the 11.5 months old
group compared to the 7.5 months old group (Mann-Whitney, p≤ 0.05). g Representative micrographs of MAC immunoreactivity at both ages
(7.5 and 11.5 months) showed MAC deposition on the basal side of RPE and in choroid. Immunoreactivity was processed with VIP, resulting in a
purple color (blue arrows) and nuclei counterstained with Methyl Green. Background immunoreactivity (0) and semi-quantitative scoring of + and
++ are given for the following examples: 7.5 months old (+), 11.5 months old (++), and negative control (0). Note the dark brown choroidal
melanocytes in the 11.5 months picture appeared surrounded by red haze due to bright field illumination. h Representative micrographs of Aβ
immunoreactivity at both ages (7.5 and 11.5 months) showed positive immunolabeling on the basal side of RPE and in choroid. Immunoreactivity
was processed with AEC, resulting in a red color (blue arrows) and nuclei counterstained as blue. Examples of semi-quantitative scores are given
as follows: 7.5 months old (++), 11.5 months old (+++), and negative control (0). i Representative micrographs of the RPE nuclei from the
11.5 months old group showed more robust NF-κB p65 immunoreactivity than the 7.5 months old group. Positive NF-κB p65 immunolabeling is
purple in RPE nuclei and indicated by blue arrows. RPE nuclei devoid of NF-κB p65 are blue and indicated by black arrows. Scale bars; 10 μm. RPE
retinal pigment epithelium, Ch choroid
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RPE/Bruch’s membrane (BM)/choroid tissues were iso-
lated and pooled for animals in each of the four treat-
ment groups (groups 1–4, N = 6) and in each age group
of the naive animals (2.5, 7.5, and 11.5 months; N ≥ 3).
To detect the MAC deposits, the tissue samples were
homogenized in 200 μL of ice-cold MAC extraction buf-
fer (50 mM Tris-HCl (pH 6.8), 150 mM NaCl, 0.1 %
SDS) containing protease inhibitor cocktail (Roche Diag-
nostics, Indianapolis IN) [20]. To preserve the MAC
protein complex, 40 μg of total protein was mixed with
equal volume of 2× non-reducing loading buffer, devoid of
boiling, and directly subjected to 5–10 % SDS-PAGE. Pro-
teins were transferred to a PVDF membrane and incu-
bated with a series of blocking buffers, primary antibody
against MAC (Table 1), and HRP conjugated secondary
antibody (R&D Systems, Minneapolis, MN). The en-
hanced chemiluminescence (ECL) method was used to de-
tect the MAC protein bands from animal groups 1–4 and
the naive animals at three different ages. The glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH)-loading con-
trol blot was done similarly using a mouse GAPDH
antibody (Table 1). All protein bands were subsequently
quantified using Image J (NIH, Bethesda MD), and the
ratio of MAC-to-GAPDH was calculated. The final
relative intensity of MAC was normalized either to the
youngest age group of 2.5 months or to the No ATAC
control group.
To detect caspase-1 cleavage and NF-κB activation, the
RPE/BM/choroid tissues were homogenized in 200 μL of
ice-cold RIPA buffer (Thermo Scientific, Waltham, MA)
containing protease inhibitor cocktail (Roche Diagnostics).
Blotting procedures followed our established protocol
[28]. For GAPDH, the same membrane was incubated in
stripping buffer and then re-probed with the GAPDH
antibody (Table 1). The protein band intensity of cleavedcaspase-1 (20kD), phosphorylated NF-κB p65 subunit (65
KDa), phosphorylated NF-κB p50 subunit (50 KDa), and
GAPDH (36kD) was individually measured using Image J
and converted into ratios relative to GAPDH. The final
relative intensity of cleaved caspase-1 p20 and phosphory-
lated NF-κB p65 was normalized to the No ATAC control
group.
For western blot detection of Aβ, both fibrillar Aβ1–40
preparation and the RIPA buffer-extracted RPE/BM/
choroid tissue lysates were mixed with 2× non-reducing
loading buffer, devoid of boiling, and directly subjected
to 5–12 % SDS-free PAGE separation. Electrophoresis
was run using MES buffer (Invitrogen, pH 7.3 ~ 7.7), and
proteins were transferred onto a 0.2-μm PVDF mem-
brane. The anti-Aβ 6E10 antibody was used to detect
the fibrillar Aβ1–40 preparation, whereas the anti-Aβ
4G8 antibody was used for tissue lysates (Table 1). Aβ
bands were developed by the ECL method. For the
membrane containing tissue lysate proteins, it was
stripped and re-processed for GAPDH detection. The in-
tensity of high-molecular species Aβ (MW > 95 kDa)
and GAPDH (36kD) was independently measured using
Image J and converted into ratios of Aβ-to-GAPDH.
The final relative intensity ratio of Aβ-to-GAPDH was
normalized to the youngest age group of 2.5 months.
ELISA for Aβ
A chemiluminescent ELISA assay specific for the detec-
tion of Aβ x-40 isoform was used to quantify Aβ in the
vitreous of rat eyes (BioLegend, Dedham, MA). 6-
month-old (N = 4) and 11.5-month-old (N = 6) rats were
sacrificed for vitreous collection. Vitreous samples were
diluted with the HRP detection antibody at a ratio of
1:1. After 18 h of detection antibody incubation at 4 °C,
the ELISA plate was then incubated with chemilumines-
cent substrates for 15 s and imaged with a microplate
F2
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linear 4-parameter regression model was used to gener-
ate the standard curve to calculate Aβ concentrations of
all vitreous samples (Gen5 version 2.04.11, BioTek).
Suspension array for IL-1β and IL-18
An ELISA-based cytokine assay for the mature, secreted
products of the inflammasome, IL-1β and IL-18, was
carried out (Bio-Plex 200 System, Bio-Rad Laboratories,
Hercules CA). Vitreous from rat eyes in groups 3–4 were
pooled. Experiments were carried out following methods
in our earlier publication [28].
Statistical analyses
Non-parametric tests were used throughout the study. For
the two group comparisons (Figs. 1c–f, 2c, 3a, c, e, 4a–c,Fig. 2 Aβ induces MAC deposition on RPE in vitro. a Western blot of fibrill
of high-molecular weight, fibrillar Aβ1–40 (MW > 170 kDa), and a concomita
with increasing incubation time. Among all the time points, the 1-week inc
pared to monomeric and dimeric species than the other time points. b Re
MAC deposits (Cy3, red) on ARPE-19 cells by combinatorial stimulation of fi
replacement abolished MAC deposition on RPE cells regardless the presenc
lar Aβ1–40 or Zym (positive control) in the presence of NHS resulted in a gr
NHS (Mann-Whitney, p≤ 0.05). The control bars indicate background level o
and this resulted in higher labeling than in HI-NHS (Mann-Whitney, p≤ 0.05
and control, in the presence of NHS, demonstrated significance between fi
not between fibrillar Aβ1–40 and zymosan (Kruskal-Wallis, p≤ 0.05)and 5a, b, e–g), a Mann-Whitney U test (one-tailed) was
used. For the three group comparisons, a Kruskal-Wallis
and post hoc Dunn’s multiple comparisons test was used
to determine differences among age groups (Fig. 1a, b) or
among stimulation regimens (Fig. 2c). All analyses were
conducted with GraphPad Prism version 6.00 for Win-
dows (GraphPad Software, La Jolla, CA). Statistical signifi-
cance was set at p ≤ 0.05.
Results
Age-dependent increases of MAC, Aβ, and NF-κB in the
RPE/choroid
In this study, we first asked whether MAC deposits in-
crease in normal aging and, if so, is it related to inflamma-
some activation in the RPE/choroid. A significant increase
in MAC (MW> 580 kDa) was evident in the RPE/choroidar Aβ1–40 preparation from six sampling time points. A general increase
nt decrease of low-molecular weight Aβ1–40 (MW < 17 kDa) are seen
ubation yielded a relatively higher percentage of fibrillar Aβ1–40 com-
presentative confocal microscopic images showed significantly more
brillar Aβ1–40/NHS or zymosan (Zym)/NHS than by NHS alone. HI-NHS
e of fibrillar Aβ1–40 or Zym. Scale bars; 20 μm. c Stimulation with fibril-
eater percentage of MAC-labeled RPE cells than in the presence of HI-
f MAC labeling as demonstrated by incubating ARPE19 cells with NHS,
). Comparisons between the three groups, fibrillar Aβ1–40, zymosan,
brillar Aβ1–40 and control, as well as between zymosan and control but
Fig. 3 (See legend on next page.)
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Fig. 3 Systemic ATAC administration did not alter NF-κB activation in RPE. a The amount of ATAC in blood was measured after 40 days of drug
administration in 7.5-month-old (1.98 μg/500 μL) and in 11.5-month-old (3.5 μg/500 μL) animals. Animals treated with ATAC showed significantly
higher ATAC blood concentrations than age-matched controls without ATAC treatment at both ages (Mann-Whitney, p≤ 0.05). b The degree of
inhibition on total complement activation by ATAC was measured by a CH50 hemolysis assay. Dilutions of the sera containing different levels of
ATAC were performed to calculate the half maximal inhibitory concentration (IC50) for total complement activity. Higher IC50 values proportionally
reflect higher levels of complement activity. Note that the IC50 levels are lower (i.e., curves shifted to the left) for ATAC-treated animals compared
to untreated controls at both ages. c ATAC administration did not affect NF-κB activation in RPE at both ages of 7.5 and 11.5 months (Mann-Whitney,
p > 0.05). d Representative micrographs of NF-κB p65 immunoreactivity in RPE/choroid from each group in c. RPE cells that demonstrate NF-κB p65
nuclear translocalization have purple nuclei and are marked by blue arrows. Unlabeled RPE nuclei are counterstained with hematoxylin (blue only) and
are marked by black arrows. Scale bar; 10 μm. RPE retinal pigment epithelium, Ch choroid. e, f RPE/choroid tissue lysates from 11.5-month-old rats with
ATAC administration contained the same amount of phosphorylated p65 subunit as in rats without ATAC in drinking-water (Mann-Whitney, p > 0.05).
The level of phosphorylated p50, however, was extremely low in both groups
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11.5 months using western blot. The normalized MAC
levels were 1.88-fold higher at 7.5 months and 2.75-fold
higher at 11.5 months when compared to the samples
obtained from 2.5-month-old rats (Fig. 1a).
Aβ is a known pathological activator of complement
cascade in Alzheimer’s disease (AD) [29]. Its ocular
presence has been reported in drusen of postmortem
eyes [30] and in rodent eyes [31]. To correlate Aβ accu-
mulation with MAC formation, we semi-quantitatively
compared the levels of high-molecular weight Aβ spe-
cies (MW > 95 kDa) among the RPE/choroid homoge-
nates from different ages. We found an age-dependent
increase of high-molecular weight Aβ from 2.5 to
11.5 months (Fig. 1b). Based on the knowledge that
biosynthesized Aβ is present in both retina and the vit-
reous compartment of the eye [32], we quantified the
Aβ in rat vitreous samples at two ages. With increasing
age, the vitreal Aβ concentration increased, by almost
80-fold, from 7.49 ± 5.16 pg/mL at 6 months to 599.10 ±
159.25 pg/mL at 11.5 months of age (Fig. 1c).
To support these results, we also assessed MAC for-
mation and Aβ accumulation in retinal cross sections by
immunohistochemistry. We demonstrated that there are
increasingly higher levels of immunoreactivity of both
MAC and Aβ in the 11.5 month animals compared to
the 7.5-month-old animals, particularly in the choroid
and the basal side of RPE (Fig. 1d, e, g, h).
NF-κB is a major transcription factor that responds to
a variety of pro-inflammatory signals by nuclear translo-
calization to upregulate the expression of target genes.
Previously, we demonstrated that Aβ activates NF-κB,
which can be specifically inhibited by NF-κB antagonists
(e.g., vinpocetine or BAY 11–7082) [28]. In the present
study, by using an antibody targeting the phosphory-
lated p65 subunit of the translocated NF-κB, we ob-
served an increase in the percentage of RPE nuclei
harboring the phosphorylated p65 subunit, mirroring
the age-related increase we observed with both MAC
and Aβ (Fig. 1f, i).Aβ promotes MAC formation in cultured ARPE-19 cells
The AD literature suggests that Aβ binds to C1q and
thereby promotes the classic complement cascade [29].
To further understand the relationship between MAC and
Aβ in the RPE/choroid, we undertook stimulation studies
to assess MAC formation on RPE in vitro. Cells were
stimulated with 0.3-μM fibrillar Aβ1–40 (MW> 170 kDa),
which was prepared from synthetic Aβ1–40 peptide and
tested by western blot. In the presence of 25 % NHS, we
observed MAC deposition on cells as ascertained by
immunocytochemistry with an anti-MAC antibody and
imaged by confocal microscopy. MAC formation was pre-
vented in control experiments in which cells were incu-
bated with 25 % HI-NHS. Levels of MAC resulting from
fibrillar Aβ1–40-stimulation were compared to MAC de-
position on cells treated with zymosan (positive control)
or serum-free medium (negative control) in the presence
of NHS or HI-NHS. NHS alone resulted in 3.73 % of RPE
cells positive for MAC. However, when combined with fi-
brillar Aβ1–40 or zymosan, MAC deposition increased to
14.91 % and 17.52 % of total RPE cells counted, respect-
ively (Fig. 2).
ATAC did not affect local NF-κB activation in RPE
While ATAC inhibits complement cascade, it is unclear
whether systemic administration of ATAC would reduce
local inflammation in the eye. To test this, animals were
treated with oral administration of ATAC in drinking-
water (60 mg/100 mL) for 40 days. Animals readily ac-
cepted drinking-water laced with ATAC ad libitum, and
no overt signs of side effects or toxicity were noted, con-
sistent with our earlier studies in which ATAC was given
in food [19].
After 40 days, the average ATAC level, as measured by
fluorescence spectroscopy, was 1.98 and 3.5 μg/500 μL
in the 7.5 and 11.5-month-old ATAC-treated rats, re-
spectively. As expected, no appreciable amount of ATAC
was evident in control rats at either age group (Fig. 3a).
A CH50 assay, which measures the amount of hemolysis
in blood due to complement activation, has been used
Fig. 4 ATAC treatment suppresses MAC deposition in the RPE/choroid. a, b At both ages of 7.5 months (a) and 11.5 months (b), western blot
analysis showed that ATAC significantly reduced MAC deposits in rat RPE/choroid (Mann-Whitney, p≤ 0.05). c At both ages, MAC immunoreactivity in
the rat RPE/choroid was significantly lower in the ATAC-treated group compared to the age-matched, No ATAC control group (Mann-Whitney,
p ≤ 0.05). d Representative micrographs from each group in c showed MAC immunoreactivity on the basal side of RPE cells and in choroid.
Blue arrows identify positive MAC deposits labeled with VIP chromogen (purple). Nuclei were counterstained as green. Scale bar; 10 μm. RPE
retinal pigment epithelium, Ch choroid
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both clinically and in experimental studies [19, 33]. Our
results showed that sera from the ATAC-treated animals
displayed a significant three- to fourfold decrease in
hemolysis relative to the sera of the control animals in both
age groups studied, thus confirming that orally adminis-
tered ATAC was present and effective at inhibiting comple-
ment activation in the sera of treated rats (Fig. 3b). Next,
we assessed the nuclear translocation of the p65 subunit in
RPE after ATAC treatment. Intriguingly, systemic adminis-
tration of ATAC did not change NF-κB p65 nuclear trans-
location when compared to control animals at 7.5 or11.5 months old (Fig. 3c, d). Further western blot analyses
of phosphorylated NF-κB p65 and p50 subunits in 11.5-
month-old rats supported this, and no significant differ-
ence in normalized band intensity was found between
animals receiving ATAC or drinking-water (Fig. 3e, f).
ATAC reduced MAC deposition in the RPE/choroid
Our earlier studies showed that ATAC was effective at
decreasing MAC in the central nervous system [19, 20],
and our next question was whether the observed sys-
temic level of ATAC was sufficient to inhibit MAC for-
mation locally in the eye. To answer this, ATAC-treated
Fig. 5 ATAC treatment inhibited inflammasome activation in the RPE/choroid. a–c At both ages of 7.5 months (a) and 11.5 months (b), western
blot analysis showed that ATAC significantly inhibited pro-caspase-1 (MW 45 kDa) cleavage into active caspase-1 (MW 20 kDa) in rat RPE/choroid
(Mann-Whitney, p≤ 0.05). c Images of western blot demonstrates a concomitant increase in the pro-caspase-1 band and decrease in the active
caspase-1 band after ATAC treatment in both age groups. d Representative micrographs illustrate immunoreactivity for IL-18, a product of inflammasome
activation, on the basal side of RPE cells and in choroid from treated and untreated animals at 7.5 and 11.5 months of age. Blue arrows indicate positive
IL-18 labeling (VIP, purple). Scale bar; 10 μm. RPE retinal pigment epithelium, Ch choroid. e IL-18 immunoreactivity in the rat RPE/choroid was significantly
downregulated by ATAC treatment. Labeling was normalized to 100 % for the untreated animals in each age group (Mann-Whitney, p≤ 0.05). f, g ELISA
measurements of vitreous samples taken from treated and untreated control animals at 11.5 months of age. Note the dramatic reduction in secreted
IL-18 (f) and IL-1β (g) concentrations after ATAC treatment (Mann-Whitney, p≤ 0.05)
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sue lysate of RPE, choroid, and BM underwent western
blot analysis. At both ages, animals treated with ATAC
demonstrated less MAC deposits (MW> 580 kDa) in theRPE/choroid compared to non-ATAC-treated animals.
Furthermore, ATAC treatment was more effective at sup-
pressing MAC in the younger group (7.5 months old). This
is intriguing, as the younger group demonstrated a lower
Zhao et al. Journal of Neuroinflammation  (2015) 12:121 Page 11 of 14ATAC concentration in sera (1.98 μg/500 μL), but with a
proportionally greater inhibition of MAC (50 % inhibition)
compared to the older group with 3.5 μg/500 μL ATAC in
sera, yet only 25 % inhibition of MAC (Figs. 3a and 4a, b).
To better understand the distribution of MAC in the ocu-
lar compartments after systemic ATAC, we assessed MAC
in retinal cross sections by immunohistochemistry. MAC
immunoreactivity was robust in the choroid and BM of
non-ATAC-treated rats at both ages, and it was reduced by
ATAC treatment at both ages (Fig. 4c, d).
ATAC suppressed inflammasome activation in the RPE/
choroid
Earlier studies in non-ocular systems suggest that MAC
formation is a potential trigger for inflammasome activa-
tion [15, 16]. Here we used an inhibitor of MAC, ATAC, to
suppress inflammasome activation in the RPE/choroid. To
test whether MAC promotes inflammasome activation, we
first examined the level of pro-caspase-1 (MW 45 kDa)
cleavage in RPE/choroid homogenates using western blot.
At both ages tested (7.5 and 11.5 months), ATAC success-
fully lowered cleaved caspase-1 (MW 20 kDa) by ~90 %
(7.5 months old) and by ~50 % (11.5 months old), when
compared to untreated controls (Fig. 5a–c). Next, we
assessed the levels of two mature products of inflamma-
some activation, IL-1β and IL-18. Compared to the ATAC
group, we found that IL-18 immunoreactivity was higher
in the untreated rat RPE/choroid. On closer visual examin-
ation, it was evident that the majority of the IL-18 immu-
nolabeling was located to the basal side of RPE and at the
RPE/choroid interface (Fig. 5d, e). We next tested secreted
levels of IL-1β and IL-18 in the vitreous by custom-made
ELISA assays. Secreted levels of IL-1β and IL-18 were 3-
and 2.5-fold lower in the vitreous of animals treated with
ATAC, respectively, compared to the untreated age-
matched controls (Fig. 5f, g).
Discussion
With normal aging, the RPE/choroid complex undergoes
many changes including drusen deposition, thickening of
BM, and thinning of the choroid. The RPE also undergoes
a number of age-associated changes, including loss of
melanin granules, accumulation of lipofuscin, changes
in pro-inflammatory cytokine secretion, and even cell
death [34, 35]. However, the cellular mechanisms under-
lying these changes in the RPE/choroid remain largely un-
known. Here, we provide a new perspective by investigating
the relationship among aging, MAC formation, and inflam-
masome activation.
Aβ facilitates MAC formation and MAC-induced inflamma-
some activation in the RPE/choroid
In AD, Aβ is a known activator of the classic comple-
ment pathway [36, 37]. In the eye, it is also abundant,co-localizes with complement factors in drusen, and
demonstrates an age-associated increase [38]. We previ-
ously showed by pathway analysis (Ingenuity, GSEA)
that the complement system is triggered by Aβ stimula-
tion of RPE in vitro [22]. However, little has been done
to assess the potential interaction between Aβ and the
complement terminal product, MAC. Here we report
age-associated increases in MAC and Aβ in the RPE/
choroid complex and soluble Aβ in the vitreous fluids
(Fig. 1). The observed age-associated MAC formation in
rat RPE/choroid is consistent with our earlier findings of
MAC deposition in BM and choroid of older postmor-
tem human eyes [10]. Since MAC and Aβ are located at
the interface of RPE and choroid, we assessed MAC for-
mation on RPE in the presence of Aβ and NHS and
showed for the first time that fibrillar Aβ is an effective
inducer of the complement cascade resulting in MAC
deposition (Fig. 2). MAC mediated inflammasome acti-
vation was shown previously in cells derived from bone
marrow and lung epithelial cells in vitro [15, 16]. Our
data support their findings and extend it to an ocular
cell type, the RPE.
From our work, and those of others, it is plausible that
the inhibition of MAC in the RPE/choroid will dampen
inflammasome activation in RPE. We found that ATAC
administration concomitantly prevented the full-length
caspase-1 from being cleaved into an enzymatically ma-
ture caspase-1 p20 subunit, the signature event of inflam-
masome activation in the same animals in which we
observed a reduction in MAC levels (Figs. 4 and 5). How-
ever, NF-κB activation, a primer for inflammasome activa-
tion, was not affected by ATAC treatment, demonstrated
by statistically equivalent amounts of the phosphorylated
p65 subunit in both retinal sections and RPE/choroid ly-
sates (Fig. 3). Intriguingly, the phosphorylated p50 sub-
unit’s level was extremely low in both ATAC and
drinking-water-treated rats. Although the p50/p65 hetero-
dimer is considered the primary form of NF-κB complex
in a wide variety of cell types, there are other active NF-
κB dimeric combinations that do not require either one or
both of them [39]. All of these suggest that ATAC’s inhibi-
tory effects spare NF-κB activation that involves p65 or
p50 and are specific for MAC. Hence, the significant re-
duction in inflammasome activation products, IL-18 and
IL-1β, which we observed after ATAC treatment, is likely
due to inefficient post-translational processing by mature
caspase-1, rather than due to altered pro-IL-18 and pro-
IL-1β production by NF-κB pathway (Fig. 5). Whether
and how the specific inhibition of NF-κB pathway can in
turn affect MAC formation remains elusive and is beyond
the scope of the current study. Although the literature
suggests NF-κB signaling regulates multiple genes in the
complement cascades, such as CFB, C3, and C4, our data
indicates no effects on C5a production when NF-κB
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file 1), and thus, likely not affecting MAC formation as
well [28, 40–42].Age-associated differences in MAC deposition and MAC
inhibition by ATAC
Another interesting outcome of our study is the difference
in ATAC efficacy in the two age groups tested. The youn-
ger rats had lower ATAC levels in blood (~2 μg/500 μL)
than the older rats (~3.5 μg/500 μL) (Fig. 3), yet there was
a proportionally greater decrease in MAC, caspase-1
cleavage, and secreted IL-18 in the younger rats compared
to the older group, suggesting that ATAC treatment was
more efficacious in the younger group (Figs. 4 and 5). The
exact mechanism behind this finding is not clear. One
possible explanation is that, with age, there is more Aβ ac-
cumulation in the rat eye, leading to more robust NF-κB
activation (p65 nuclear translocalization) and more MAC
deposition, which is not proportional to the increase in
ATAC concentration, or its activity, and thus over-
whelmed ATAC’s suppressive effects leading to reduceFig. 6 Proposed inflammasome activation mechanisms with Aβ and MAC
increased accumulation of Aβ that acts as a “Signal 1” to activate the NF-κB
and pro-IL-1β (2). Next, assembly and activation of the NLRP3 inflammasom
membrane (3). NLRP3 activation results in pro-caspase-1 auto-cleavage (4).
enzyme to facilitate the production and secretion of active, mature IL-18 an
MAC-induced inflammasome activation on RPEefficacy in the older rats compared to that observed in
younger rats (Figs. 1 and 2).Conclusions
In summary, we have shown an age-dependent increase in
Aβ, MAC, and NF-κB in rat RPE/choroid. We have also
demonstrated that Aβ, a drusen component, is an effective
priming signal for NF-κB activation in vitro and in vivo
[28] and promotes the NLRP3 inflammasome activation
in the rat eye [21]. Suppression of MAC leads to a con-
comitant suppression of NLRP3 inflammasome activation
measured by caspase-1 cleavage and secretion of mature
IL-18 and IL-1β as depicted in the schematic summary
(Fig. 6). An inherent limitation of this study is that rodents
do not have a macula/fovea, and thus renders this animal
model less useful as it does not reproduce “macular” dis-
ease. However, this model is useful to understand the
basic, cellular changes in the retina that are associated
with chronic inflammation, aging, and age-related retinal
diseases. Our work suggests that MAC-induced NLRP3
inflammasome activation may be an important cause ofin RPE/choroid. Age-associated changes in RPE/choroid include an
pathway (1). This upregulates the transcription of NLRP3, pro-IL-18
e is triggered by MAC deposition (“Signal 2”) on the RPE cell
The cleaved caspase-1 then functions as a cytokine-processing
d IL-1β (5). ATAC compound works as a MAC inhibitor, suppressing
Zhao et al. Journal of Neuroinflammation  (2015) 12:121 Page 13 of 14the chronic pro-inflammatory environment in the outer
retina of a normal aging eye.
Additional file
Additional file 1: C5a is not affected by Vinpocetine-mediated
NF-κB inhibition. Description of data: Since the intraocular Aβ1–40
injection has been previously implicated in promoting NF-κB activation
and NLRP3 inflammasome activation [21], we assessed the level of
activated C5 (C5a) as a surrogate marker for complement activation and
MAC formation when NF-κB activity was specifically inhibited by vinpocetine.
Western blot of retina protein lysates shows equal amounts of C5a (MW 41
KDa; rabbit polyclonal C5a complement antibody, cat# 250565) in the
vinpocetine-treated group, when compared to vehicle controls
(Mann-Whitney, p > 0.05; N = 5). For a full description of the experimental
procedures, readers are referred to our previous publication [28].
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